The COVID-19 pandemic has reshaped attitudes toward public health, fiscal policy, and the state’s role in the economy. Demands for greater supply-chain resilience and strategic autonomy in developing ...More
EJ Insight2022-06-07
Recent conversations about the global economy and markets have been defined by a set of recurring questions. While there are many moving parts that are difficult to capture in a single clear picture, ...More
EJ Insight2022-06-07
Last month, when the Covid-19 death toll in the United States reached a million, China’s government and state media took delight in mocking and shaming America in its moment of national grief. A Chine ...More
EJ Insight2022-06-06
The World Economic Forum’s first meeting in more than two years was markedly different from the many previous Davos conferences that I have attended since 1995. It was not just that the bright snow an ...More
EJ Insight2022-06-03
In 2021, the big debate about the outlook for the global economy focused on whether the rising inflation in the United States and other advanced economies was transitory or persistent. Key central ban ...More
EJ Insight2022-06-01
The rise of China into the upper echelons of the world economic order underscores the sway it has over how the global economy performs from the perspective of its appetite for commodities from grains ...More
EJ Insight2022-06-01
The fifth wave of COVID-19 epidemic in Hong Kong has been severe. In order to curb the spread of the epidemic, the government adopted stricter anti-epidemic measures, including banning dining in resta ...More
EJ Insight2022-05-30
The United States Food and Drug Administration’s recent decision to limit the use of the Johnson & Johnson COVID-19 vaccine to adults who cannot or will not get another vaccine will have profound ...More
EJ Insight2022-05-27
Global food prices are soaring. The United Nations Food and Agriculture Organization’s Food Price Index – which covers a basket of basic food commodities (cereals, meat, dairy, vegetable oils, and sug ...More
EJ Insight2022-05-24
君實生物(01877) 內幕消息－ VV116對比PAXLOVID早期治療輕中度COVID-19的III期註冊 ...全文
君實生物(01877) 海外監管公告 - 上海君實生物醫藥科技股份有限公司關於VV116對比PAXLOVID早 ...全文
君實生物(01877) 內幕消息－ VV116對比PAXLOVID早期治療輕中度COVID-19的III期註冊 ...全文
Risk assets have gotten off to a historically poor start in 2022, a year in which seemingly diversified portfolios have been generating undiversified returns. Stocks and government bonds are down by d ...More
EJ Insight2022-05-20
